Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
about
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionPredictive biomarkers in precision medicine and drug development against lung cancerTargets for Ibrutinib Beyond B Cell MalignanciesDiscovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.Characterization of Human Cancer Cell Lines by Reverse-phase Protein ArraysIbrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaMolecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignanciesIbrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsAuranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaIbrutinib targets mutant-EGFR kinase with a distinct binding conformation.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.Integrative cancer pharmacogenomics to establish drug mechanism of action: drug repurposing.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.Role of Bruton's tyrosine kinase in B cells and malignancies.Non-small-cell lung cancer.Resolution of lung adenocarcinoma after discontinuation of ibrutinib.Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
P2860
Q26783430-966F50E6-3B0D-4502-AA33-E42D9F2A0001Q26824536-FA73CB27-0B9C-45FB-A051-5ECF948078F0Q28087772-5FBF1BBC-A6F8-43BF-B326-87FDABF0AC5CQ33566948-D6C71146-9209-498C-9ACB-3CB5CF301619Q33672190-306BDC12-2D2C-4C42-AD57-F4C74550C0C8Q33882864-61E827F7-A111-42CE-A16C-D205FAC82CB7Q33909648-8A76F3A0-3EEC-4BAE-8F5E-7CD2BFE056FBQ34534572-B27B9239-98C2-4FA0-95E4-0FAA9F15C5A2Q35828688-95170A14-CBDD-43F0-918C-CAC7EA7C7EBAQ35944914-2CD549D3-1489-4EA8-BDD0-09B85FD8B229Q35979385-07BA4519-B29B-4EDC-A553-7CB1DD2200A6Q36517276-230F84C6-7F82-4968-B73A-FE9F5554BD47Q36544565-DADB0192-C00B-4957-946A-623408FEB104Q36772192-F014EF12-2571-483B-93F8-3FC6ED2CE626Q37180382-9EA6C742-2122-4DB5-BC2D-B4E57F55B26EQ37688439-E98A6E00-7AA9-4625-A7AD-3931283CDABAQ38818283-703A3BAE-72BA-4A18-B4C0-13718D8A0E68Q38857067-1C219AA6-8AFF-4717-BE03-5E203E4ABC0EQ42381432-493121C1-A682-435A-93DA-92E5C3D73275Q45944710-169D5B52-39B8-4595-A813-22D510CD4CBEQ46055970-D34FB15E-EC82-417C-8E6C-642C9686547EQ47445525-043CA435-C5B5-426F-BD67-361F975583A4Q49888075-8B9263B4-DEE2-4342-BC87-0E65B1C1EF3EQ51021428-AEC4D6A5-F6AD-49EA-9EDB-B82C84DC2CECQ51630250-C6268F40-E9CC-400E-88A0-82476D30D7F2Q52645038-B1888665-7A4D-4476-B659-B0B2E2CE4F8FQ53963822-658A7E2E-A534-4A9B-8C2A-FD5CE84ACEFEQ54977394-191B09AC-6C2E-4D98-AD6C-68769FD382AE
P2860
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@ast
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@en
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@nl
type
label
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@ast
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@en
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@nl
prefLabel
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@ast
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@en
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@nl
P2093
P2860
P356
P1476
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells
@en
P2093
Bingbing Dai
Bingliang Fang
Jack A Roth
John Minna
Kathryn A Gold
Liang Zhang
Michael Wang
Shuhong Wu
P2860
P356
10.1093/JNCI/DJU204
P407
P577
2014-09-10T00:00:00Z